TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With COVID-19 Interstitial Pneumonia

Inclusion Criteria: * SARS-CoV2 Infection diagnosed by rt-PCR * CT-scan confirmed interstitial pneumonia * Hospital admission from less than 24h * P/F ratio \>150 mmHg * Written Informed Consent Exclusion Criteria: * Age \<18 ys or \>65 * Patients in mechanical ventilation at time of admission * Severe Hearth failure (NYHA 3 or 4) * QTc \> 470 ms or \>500 ms in wide QRS patients * Severe History of Chronic Ischemic Heart Disease, defined as history of Major Adverse Cardiovascular Event and/or recent (one year) revascularization. * History of recurrent Deep Venous Thrombosis and Pulmonary Embolism or established thrombophilic conditions (e.g. history of anti-phospholipid antibodies, …) * Active Bacterial or Fungal Infection * Hematological cancer * Metastatic or intractable cancer * Pre-existent neurodegenerative disease * Severe Hepatic Impairment, * History of acute diverticular disease or intestinal perforation * HBsAg positive and/or HBV-DNA positive patients * Severe Renal Failure (Creatinine Clearance \<30ml/h) * Active Herpes zoster infection * Patients with active or latent TB * Severe anemia (Hb\<9g/dl) * Lymphocyte count below 750/mcl * Neutrophil count below 1000/mcl * Platelet count below 50000/mcl * Pregnancy or Lactation * History of intolerance to the experimental drugs or excipients * Degenerative maculopathy or other relevant retinal disease * Inability to give informed consent (severe transitory or permanent mental impairment, incapacitation)